- Home
- SNY vs BMY Comparison
SNY vs BMY Comparison
Compare SNY & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNY | BMY |
|---|---|---|
| Founded | 1994 | 1887 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.7B | 113.5B |
| IPO Year | 2001 | 2006 |
Fundamental Metrics
Financial Performance| Metric | SNY | BMY |
|---|---|---|
| Price | $41.62 | $61.13 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 28 |
| Target Price | $53.61 | ★ $65.25 |
| AVG Volume (30 Days) | 3.1M | ★ 11.9M |
| Earning Date | 10-30-2026 | 10-29-2026 |
| Dividend Yield | ★ 5.82% | 4.10% |
| EPS Growth | N/A | ★ 178.46 |
| EPS | N/A | ★ 2.93 |
| Revenue | N/A | ★ $48,194,000,000.00 |
| Revenue This Year | $1.82 | $3.54 |
| Revenue Next Year | $6.51 | N/A |
| P/E Ratio | ★ $6.14 | $21.05 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $39.07 | $42.52 |
| 52 Week High | $52.68 | $68.64 |
Technical Indicators
Market Signals| Indicator | SNY | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 53.91 | 49.93 |
| Support Level | $41.19 | $59.91 |
| Resistance Level | $41.88 | $62.77 |
| Average True Range (ATR) | 0.65 | 1.81 |
| MACD | 0.34 | 0.45 |
| Stochastic Oscillator | 85.03 | 67.61 |
Price Performance
Historical ComparisonAbout SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.